ADIL
Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc
$ADIL Reports Positive Q1 Financial Results and Advances Regulatory Strategy and Partnership Discussions
Adial Pharmaceuticals' Q1 2023 financial report showed $2.3m cash and cash equivalents. The company engaged Keswick Group to aid in partnering activities and sold Purnovate to Adovate, receiving $450k upfront and expecting up to $83m in milestones, a single-digit royalty, & 19.9% equity. With ongoing regulatory meetings for AD04, a potential treatment for opioid use disorder, gambling, and obesity, the business update is positive.
4mo ago
$ADILAdial Pharmaceuticals Inc
$ADIL Reports Strong Financial Position and Advancements in Clinical Trials
Adial Pharmaceuticals has announced fiscal year 2022 results with $4 million cash on hand and significant progress towards obtaining regulatory approval for AD04, a drug aimed at reducing heavy drinking days in those with Alcohol Use Disorder. The company has also engaged the Keswick Group to support its partnering activities and entered an agreement to sell the assets of its subsidiary, Purnovate, to Adovate, potentially earning up to $83 million in consideration. However, forward-looking statements carry risks and uncertainties that may affect actual results.
5mo ago
$ADIL